reason report
upa get class product thrombosi label target-price
bottom line friday august fda approv jak
inhibitor rinvoq upadacitinib dose treatment
adult patient moder sever activ rheumatoid arthriti ra
inadequ respons intoler methotrex
approv wide anticip base posit result
phase studi upa patient treat ra pivot studi
rinvoq label consist clinic trial result
includ methotrex nave diseas label safeti liabil
consist two approv jak tofacitinib baricitinib
rinvoq black box warn increas risk seriou infect
malign thrombosi despit better safeti profil
pivot trial howev safeti languag exclud specif mention
upadacitinib associ thrombosi event despit
inclus label suggest fda regard
event class liabil regardless report pivot
trial standard could neg gilead mp filgotinib
depend greater specif lower advers event liabil
long term posit increas probabl success
po upadicitinib rinvoq long term risk-
adjust peak sale forecast upa increas
new upa forecast consensu higher
base chang increas price
target reiter outperform rate
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm dilut ep includ option expens present
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target per share stock rate outperform
establish independ pharmaceut compani transit new
phase term scale oper effici plan acquisit allergan earli
allergan bring new revenu market categori outsid
current product portfolio allergan esthet busi one endur franchis
industri unlik advers affect mani risk face tradit
necessarili fan consolid sake see bring
disciplin decis allergan portfolio confid maxim
valu allergan esthet busi cash flow without disrupt effect
busi unit innov cultur commerci effect ad allergan dilut
abbvi exposur humira posit offer compani
signific opportun oper effici synergi alreadi
disclos face mani challeng humira franchis rebat reform patent
challeng biosimilar pathway chang patent reform product cash flow
seem rel secur beyond two cornerston hematolog busi
grow strongli sever year least emerg combin neurosci portfolio
gener signific revenu posit cash flow earli import
pipelin program combin compani come skyrizi venclexta imbruvica
new indic signific increment opportun probabl allergan
neurolog migrain psychiatri schizophrenia program boost back
indic compani long sinc abandon see combin compani
deliv mid-singl digit revenu growth high singl digit ep growth
offer investor attract low doubl digit dividend growth dividend yield
today regard portfolio particularli innov today view
stock compel trade vehicl mid reason post deal valuat
rang
better efficaci margin better safeti less alarm warn upa label
expect rinvoq receiv class label similar black box warn pfizer xeljanz
lilli olumi seriou infect malign thrombosi manag avoid
alarm word fatal event higher rate all-caus mortal specif
describ xeljanz olumi label exhibit
exhibit comparison black warn
xeljanz olumi rinvoq prescrib inform
although everi trial differ compar pivot trial xeljanz olumi rinvoq
tnf inadequ respond rinvoq higher percentag patient reach placebo-
adjust american colleg rheumatolog score slightli lower percentag reach
much better result diseas remiss measur diseas activ score
xeljanzolumiantrinvoqblack warn headlineseri infect mortal malign thrombosisseri infect malign thrombosisseri infect malign thrombosisthrombosi relat warningsrheumatoid arthriti patient least one cardiovascular cv risk factor higher rate all-caus mortal thrombosi xeljanz mg twice daili vs mg twice daili tnf blockersthrombosi includ deep venou thrombosi pulmonaryembol arteri thrombosi fatal occurredin patient treat olumi patient symptomsof thrombosi evalu promptli thrombosi includ deep vein thrombosi pulmonari embol arteri thrombosi occur patient treat januskinas inhibitor use treat inflammatori condit inc
exhibit comparison placebo-adjust efficaci data tnf inadequ respond
xeljanz olumi rinvoq prescrib inform
rinvoq larg compar olumi pbo-adj pbo-adj pbo-adj
virtual exhibit
exhibit comparison placebo-adjust efficaci data cdmard inadequ respond
xeljanz olumi rinvoq prescrib inform
rinvoq label look better xeljanz inadequ respond higher percentag
patient reach pbo-adj acr respons vs higher percentag reach
acr respons vs much higher percentag reach diseas remiss
exhibit comparison placebo-adjust efficaci data inadequ respond
xeljanz olumi rinvoq prescrib inform
lastli efficaci side rinvoq show similar effect xeljanz term chang
modifi total sharp score base radiograph endpoint exhibit
exhibit comparison chang modifi total sharp score
xeljanz olumi rinvoq prescrib inform
upadacitinib get class label major risk filgotinib seem like well
although rinvoq demonstr better safeti pivot trial lower venou
thromboembol event vte rate compar placebo humira fda still insist
appli class label risk give product black box warn thrombosi risk base
occurr event tofacitinib baricitinib class label
limit rinvoq commerci opportun expect whole jak class includ much-
anticip safer jak inhibitor filgotinib receiv similar label best-in-class
commerci capabl expect rinvoq outperform jak includ filgotinib
multipl indic develop ra ibd ultim commerci
rinvoq launch ra week derm ibd label expans way
indic rinvoq avail late august second line treatment ra
methotrex set annual list price rinvoq larg
line jak also submit european medicin agenc ema applic
upadacitinib late last year approv later year upadacitinib
current studi late stage trial multipl diseas dermatolog inflammatori
bowel diseas ibd base clinicaltrail gov may expect phase readout atop
dermat ad crohn diseas cd psoriat arthriti first half
safeti overview label
accord label patient treat rinvoq pivot studi
experienc upper respiratori tract infect urti higher placebo arm small
differ observ common advers event includ nausea cough
pyrexia three placebo-control studi ra-ii iv seriou infect rate twice
high rinvoq group vs placebo pt year vs pt year major
differ seriou infect rate seen high dose group low dose
group accord exposur dataset term malign risk low dose
rinvoq group appear larg placebo pt year vs high
dose rinvoq group show higher risk compar placebo vs convers mtx-
control studi malign rate three time higher low dose group vs mtx-control
arm vs wherea high dose group zero malign case rinvoq placebo
group venou thrombosi event placebo-control studi mtx-control
studi rinvoq group venou thrombosi event low dose venou thrombosi event
high dose arteri thrombosi event high dose compar group venou
thrombosi event base exposur dataset high dose low dose rinvoq group
appear similar low venou arteri thrombosi event rate
increas risk adjust revenu pt
base approv increas po upadacitinib/rinvoq
peak global revenu forecast upa increas risk adjust upa
revenu forecast larg in-lin guidanc new upa forecast
consensu higher base chang increas
price target reiter outperform rate stock
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
larg cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag larg cap larg molecul therapeut compani mid-
term growth tail risk celg averag consensu
ep multipl appli current ep estim give valu
use revenu multipl similar compani consensu
sale appli revenu estim give valu
lastli dcf valuat given wacc termin cash flow growth rate
begin humira biosimilar entri give present valu averag
three method current price target upon complet analysi
quarterli result revisit price target present remain unchang
risk view outlook valuat includ major chang price outlook
reimburs coverag label competit posit humira compani main product
risk includ commerci develop disappoint compani follow-on program
inflammatori diseas imbruvica venclexta expand hematolog malign well
competit posit compani next-gener hcv therapi also compani remain
highli lever commit grow dividend reduct forecast ebitda due
neg busi trend would place compani capit alloc strategi dividend growth
risk opportun upsid expect includ stronger-than-expect price volum
share humira emerg tangibl demand underappreci element
compani early-to-mid stage pipelin asset potenti label expans opportun late stage
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view
phase trial reuslt newly-diagnos
supplementari approv cll result front-
phase trial front-lin aml
svb leerink llc research compani file
analysi stock price svb leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep celg
svb leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current svb leerink dcf marketed/l stage program
sourc svb leerink llc estim compani file factset
